- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 5/097 - Tripeptides le premier amino-acide étant hétérocyclique, p.ex. Pro, His, Trp, p.ex. thyrolibérine, mélanostatine
Détention brevets de la classe C07K 5/097
Brevets de cette classe: 230
Historique des publications depuis 10 ans
|
29
|
27
|
30
|
17
|
21
|
16
|
22
|
18
|
19
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Onyx Therapeutics, Inc. | 71 |
9 |
| Sederma | 246 |
7 |
| Hoffmann-La Roche Inc. | 3255 |
5 |
| Northwestern University | 3272 |
5 |
| Trustees of Tufts College | 818 |
5 |
| Wisconsin Alumni Research Foundation | 3819 |
4 |
| Enanta Pharmaceuticals, Inc. | 421 |
4 |
| Shanghai Lumosa Therapeutics Co., Ltd. | 15 |
4 |
| University of Cincinnati | 833 |
4 |
| viDA Therapeutics Inc. | 16 |
4 |
| Onkure, Inc. | 21 |
4 |
| The Regents of the University of California | 19493 |
3 |
| The Johns Hopkins University | 5524 |
3 |
| Cornell University | 3190 |
3 |
| Escape Therapeutics, Inc. | 28 |
3 |
| Molecular Transfer, Inc. | 32 |
3 |
| Research & Business Foundation Sungkyunkwan University | 1785 |
3 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 805 |
3 |
| ValiRX plc | 3 |
3 |
| INSUSENSE ApS | 22 |
3 |
| Autres propriétaires | 148 |